Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Buy” at StockNews.com

StockNews.com downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a report published on Saturday.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Trading Up 2.4 %

SUPN stock opened at $32.84 on Friday. Supernus Pharmaceuticals has a one year low of $25.53 and a one year high of $40.28. The firm has a 50-day moving average of $36.62 and a two-hundred day moving average of $35.27. The firm has a market capitalization of $1.83 billion, a PE ratio of 30.69 and a beta of 0.83.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 in the last 90 days. 9.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Pacer Advisors Inc. raised its position in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after acquiring an additional 403,028 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Supernus Pharmaceuticals by 124.8% during the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock valued at $15,326,000 after purchasing an additional 235,257 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Supernus Pharmaceuticals by 248.0% during the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock valued at $10,581,000 after purchasing an additional 208,552 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at $6,847,000. Finally, Great Lakes Advisors LLC bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth $6,131,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.